226 related articles for article (PubMed ID: 38018486)
1. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
Choi D; Gonzalez-Suarez AM; Dumbrava MG; Medlyn M; de Hoyos-Vega JM; Cichocki F; Miller JS; Ding L; Zhu M; Stybayeva G; Gaspar-Maia A; Billadeau DD; Ma WW; Revzin A
Adv Sci (Weinh); 2024 Feb; 11(5):e2303088. PubMed ID: 38018486
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
3. Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies.
Choi D; Gonzalez-Suarez AM; Billadeau DD; Ma WW; Stybayeva G; Revzin A
Methods Mol Biol; 2023; 2679():219-231. PubMed ID: 37300619
[TBL] [Abstract][Full Text] [Related]
4. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
[TBL] [Abstract][Full Text] [Related]
5. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
7. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
9. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.
Demyan L; Habowski AN; Plenker D; King DA; Standring OJ; Tsang C; St Surin L; Rishi A; Crawford JM; Boyd J; Pasha SA; Patel H; Galluzzo Z; Metz C; Gregersen PK; Fox S; Valente C; Abadali S; Matadial-Ragoo S; DePeralta DK; Deutsch GB; Herman JM; Talamini MA; Tuveson DA; Weiss MJ
Ann Surg; 2022 Sep; 276(3):450-462. PubMed ID: 35972511
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
[TBL] [Abstract][Full Text] [Related]
12. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients.
Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y
Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
Sandhya S; Hogenson TL; Fernandez-Zapico ME
EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
[TBL] [Abstract][Full Text] [Related]
14. Organoid technology for personalized pancreatic cancer therapy.
Bengtsson A; Andersson R; Rahm J; Ganganna K; Andersson B; Ansari D
Cell Oncol (Dordr); 2021 Apr; 44(2):251-260. PubMed ID: 33492660
[TBL] [Abstract][Full Text] [Related]
15. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
16. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Yomtoubian S; Ng I; Tiriac H; Lowy AM; Zou J; Engle DD
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38051586
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
[TBL] [Abstract][Full Text] [Related]
18. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer.
Watanabe S; Yogo A; Otsubo T; Umehara H; Oishi J; Kodo T; Masui T; Takaishi S; Seno H; Uemoto S; Hatano E
BMC Cancer; 2022 May; 22(1):489. PubMed ID: 35505283
[TBL] [Abstract][Full Text] [Related]
19. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
20. Standardized Methods Using EUS-guided Fine-needle Biopsy and a Minimal Medium Creates Three Pancreatic Cancer Organoids.
Ishida Y; Tsunoda T; Hamada Y; Tsuchiya N; Koga T; Kitaguchi T; Matsumoto K; Matsumoto S; Sasaki T; Nakashima R; Ishii F; Kajiwara M; Shirasawa S; Hasegawa S; Hirai F
Anticancer Res; 2022 Aug; 42(8):4103-4109. PubMed ID: 35896269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
